ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO817

Intradialytic Relative Blood Volume Changes and All-Cause Mortality Among Hemodialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Preciado, Priscila, Renal Research Institute, New York, New York, United States
  • Zhang, Hanjie, Renal Research Institute, New York, New York, United States
  • Thijssen, Stephan, Renal Research Institute, New York, New York, United States
  • Kooman, Jeroen, Maastricht University Medical Centre, Maastricht, Netherlands
  • van der Sande, Frank, Maastricht University Medical Centre, Maastricht, Netherlands
  • Kotanko, Peter, Renal Research Institute, New York, New York, United States
Background

Adequate volume control is a major challenge in hemodialysis (HD) patients, as both fluid overload and depletion are associated with increased mortality. Ultrafiltration is the only means for fluid removal in anephric patients. Whenever the ultrafiltration rate (UFR) exceeds the plasma refilling rate, the blood volume declines and hypotension may ensue. Relative blood volume (RBV) monitoring during HD is used as a means to tailor UFR. Our goal was to explore the association between intradialytic RBV levels and all-cause mortality in maintenance HD patients

Methods

We conducted a retrospective analysis of data from HD patients dialyzed in 17 Renal Research Institute clinics between 1/2012 and 12/2016. A 6-months baseline period preceded a follow-up. Censoring events were change in treatment modality, transfer to another clinic, and study end. RBV was measured using the Critline monitor. RBV was assessed after 25%, 50%, 75% and 100% of the elapsed treatment time. The relationship between mortality and RBV at these four time points was analyzed using Cox proportional hazards models with spline terms

Results

We studied 842 patients with a total of 28,119 HD treatments (mean age 61.0±14.8 years, 50% whites, 62% males, 56% had diabetes mellitus, 22% had congestive heart failure). Median follow-up time was 30.8 months. The mortality rate was 11.5/100 patient years. We identified specific intradialytic RBV levels after 25%, 50%, 75% and 100% of the elapsed dialysis treatment time that were associated with a significantly lower all-cause mortality [Fig 1].

Conclusion

We showed in a large cohort of HD patients that specific RBV levels are associated with better outcomes. These findings corroborate the notion that RBV monitoring has the potential to improve outcomes. Prospective studies are warranted to explore if active attainment of these RBV levels translates into improved patient outcomes.

Fig 1. Intradialytic RBV ranges associated with hazard ratios significantly below 1.0 for all-cause mortality.